LENZ Therapeutics Inc. (LENZ)
NASDAQ: LENZ
· Real-Time Price · USD
27.73
0.10 (0.36%)
At close: May 15, 2025, 2:30 PM
0.36% (1D)
| Bid | 27.62 |
| Market Cap | 780.49M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -49.77M |
| EPS (ttm) | 0.66 |
| PE Ratio (ttm) | 42.02 |
| Forward PE | -10.35 |
| Analyst | Buy |
| Ask | 27.82 |
| Volume | 60,254 |
| Avg. Volume (20D) | 248,036 |
| Open | 28.03 |
| Previous Close | 27.63 |
| Day's Range | 27.00 - 27.87 |
| 52-Week Range | 14.42 - 38.93 |
| Beta | 0.40 |
About LENZ
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol LENZ
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for LENZ stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts6 months ago
+5.48%
LENZ Therapeutics shares are trading higher after ...
Unlock content with
Pro Subscription
6 months ago
-2.86%
LENZ Therapeutics shares are trading higher after the company announced the FDA accepted its new drug application for LNZ100 for the treatment of Presbyopia.
